Clinical Takeaway
Trauma-focused treatments remain effective for PTSD even when patients are actively using cannabis, including those with co-occurring substance use disorders. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis clarifies whether cannabis use compromises treatment response to evidence-based trauma-focused therapies in patients with comorbid PTSD and substance use disorders, addressing a critical clinical gap since many practitioners remain uncertain about treating these patients effectively. The findings establish whether trauma-focused interventions maintain efficacy across cannabis use status, which directly informs treatment planning and patient selection for this high-risk population. Understanding differential treatment outcomes by cannabis use status enables clinicians to set appropriate expectations and optimize therapeutic approaches for individuals with these highly prevalent co-occurring conditions.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis addresses a clinically relevant question about whether cannabis use compromises the effectiveness of trauma-focused therapies in patients with co-occurring PTSD and substance use disorders, drawing data from four RCTs within a larger individual patient meta-analysis. While the study design is methodologically sound, several important caveats warrant consideration: the analysis is limited to a subset of trials with available cannabis use data, causality cannot be established from observational comparisons within RCTs, and the heterogeneity of cannabis use patterns (frequency, potency, timing relative to treatment) may obscure meaningful subgroup differences. Additionally, cannabis use was likely not a primary randomization variable, creating potential confounding by factors such as symptom severity or motivation for treatment that could influence both cannabis use and therapy outcomes. From a clinical standpoint, until we have definitive evidence that cannabis use undermines trauma-focused treatment efficacy in this population, providers should not categorically exclude motivated patients with PTSD and co-occurring cannabis use from evidence